Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis

Arnaud Bisson, Alexandre Bodin, Julien Herbert, Thibaut Lacour, Christophe Saint Etienne, Bertrand Pierre, Nicolas Clementy, Pierre Deharo, Dominique Babuty, Laurent Fauchier, Arnaud Bisson, Alexandre Bodin, Julien Herbert, Thibaut Lacour, Christophe Saint Etienne, Bertrand Pierre, Nicolas Clementy, Pierre Deharo, Dominique Babuty, Laurent Fauchier

Abstract

Background The incidence of conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) with early and later generation prostheses remains debated. Methods and Results Based on the administrative hospital-discharge database, we collected information for all patients treated with TAVR between 2010 and 2019 in France. We compared the incidence of PPI after TAVR according to the type and generation of valve implanted. A total of 49 201 patients with aortic stenosis treated with TAVR using the balloon-expandable (BE) Edwards SAPIEN valve (early Sapien XT and latest Sapien 3) or the self-expanding (SE) Medtronic CoreValve (early CoreValve and latest Evolut R) were found in the database. Mean (SD) follow-up was 1.2 (1.5 years) (median [interquartile range] 0.6 [0.1-2.0] years). PPI after the procedure was reported in 13 289 patients, among whom 11 010 (22.4%) had implantation during the first 30 days. In multivariable analysis, using early BE TAVR as reference, adjusted odds ratio (95% CI) for PPI during the first 30 days was 0.88 (0.81-0.95) for latest BE TAVR, 1.40 (1.27-1.55) for early SE TAVR, and 1.17 (1.07-1.27) for latest SE TAVR. Compared with early BE TAVR, the adjusted hazard ratio for PPI during the whole follow-up was 1.01 (0.95-1.08) for latest BE TAVR, 1.30 (1.21-1.40) for early SE TAVR, and 1.25 (1.18-1.34) for latest SE TAVR. Conclusions In patients with aortic stenosis treated with TAVR, our systematic analysis at a nationwide level found higher rates of PPI than previously reported. BE technology was independently associated with lower incidence rates of PPI both at the acute and chronic phases than SE technology. Recent generations of TAVR were not independently associated with different rates of PPI than early generations during the overall follow-up.

Keywords: aortic stenosis; pacemaker; transcatheter aortic valve implantation.

Figures

Figure 1. Incidence of permanent pacemaker implantation…
Figure 1. Incidence of permanent pacemaker implantation in patients treated with TAVR, according to type and generation of device.
BE indicates balloon‐expandable; Early BE, Edwards Sapien XT; Early SE, Medtronic Corevalve; Latest BE, Edwards Sapien 3; Latest SE, Medtronic Evolut; SE, self‐expandable; and TAVR, transcatheter aortic valve replacement.

References

    1. Nguyen V, Michel M, Eltchaninoff H, Gilard M, Dindorf C, Iung B, Mossialos E, Cribier A, Vahanian A, Chevreul K, et al. Implementation of transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2018;71:1614–1627.
    1. Deharo P, Bisson A, Herbert J, Lacour T, Saint Etienne C, Grammatico‐Guillon L, Porto A, Collart F, Bourguignon T, Cuisset T, et al. Impact of Sapien 3 balloon‐expandable versus evolut R self‐expandable transcatheter aortic valve implantation in patients with aortic stenosis: data from a nationwide analysis. Circulation. 2020;141:260–268.
    1. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic‐valve replacement in intermediate‐risk patients. N Engl J Med. 2016;374:1609–1620.
    1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al.; PARTNER 3 Investigators . Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695–1705.
    1. Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, et al. 2‐year outcomes in patients undergoing surgical or self‐expanding transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;66:113–121.
    1. Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat G, Okuyama K, Kashif M, Chakravarty T, et al. A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging. 2017;10:1139–1147.
    1. Vlastra W, Chandrasekhar J, Munoz‐Garcia AJ, Tchetche D, de Brito FS Jr, Barbanti M, Kornowski R, Latib A, D'Onofrio A, Ribichini F, et al. Comparison of balloon‐expandable vs. self‐expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER‐collaboration. Eur Heart J. 2019;40:456–465.
    1. De Torres‐Alba F, Kaleschke G, Diller GP, Vormbrock J, Orwat S, Radke R, Reinke F, Fischer D, Reinecke H, Baumgartner H. Changes in the pacemaker rate after transition from Edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height. JACC Cardiovasc Interv. 2016;9:805–813.
    1. Thiele H. A 2x2 randomized trial of self‐expandable vs balloon‐expandable valves and general vs local anesthesia in patients undergoing transcatheter aortic valve implantation. Presented at tct, 23 September, San Diego, CA; 2018.
    1. Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R, Motreff P, Leprince P, Verhoye JP, Manigold T, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017;70:42–55.
    1. Van Belle E, Vincent F, Labreuche J, Auffret V, Debry N, Lefevre T, Eltchaninoff H, Manigold T, Gilard M, Verhoye JP, et al. Balloon‐expandable versus self‐expanding transcatheter aortic valve replacement: a propensity‐matched comparison from the FRANCE‐TAVI registry. Circulation. 2020;141:243–259.
    1. Sheng SP, Strassle PD, Arora S, Kolte D, Ramm CJ, Sitammagari K, Guha A, Paladugu MB, Cavender MA, Vavalle JP. In‐hospital outcomes after transcatheter versus surgical aortic valve replacement in octogenarians. J Am Heart Assoc. 2019;8:e011206 DOI: 10.1161/JAHA.118.011206.
    1. Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, El‐Chami MF, Herrmann HC, Mack M, Makkar RR, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (placement of aortic transcatheter valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60–69.
    1. Alkhalil A, Lamba H, Deo S, Bezerra HG, Patel SM, Markowitz A, Simon DI, Costa MA, Davis AC, Attizzani GF. Safety of shorter length of hospital stay for patients undergoing minimalist transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018;91:345–353.
    1. Ream K, Sandhu A, Valle J, Weber R, Kaizer A, Wiktor DM, Borne RT, Tumolo AZ, Kunkel M, Zipse MM, et al. Ambulatory rhythm monitoring to detect late high‐grade atrioventricular block following transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;73:2538–2547.
    1. Kiani S, Kamioka N, Black GB, Lu MLR, Lisko JC, Rao B, Mengistu A, Gleason PT, Stewart JP, Caughron H, et al. Development of a risk score to predict new pacemaker implantation after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:2133–2142.
    1. Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, Elgin E, Donato A. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016;9:2189–2199.
    1. Rodes‐Cabau J, Ellenbogen KA, Krahn AD, Latib A, Mack M, Mittal S, Muntane‐Carol G, Nazif TM, Sondergaard L, Urena M, et al. Management of conduction disturbances associated with transcatheter aortic valve replacement: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74:1086–1106.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera